Please assess the completion status of the following clinical trial:

Trial Title: Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or nonpregnant female~* Provide written informed consent prior to study-related procedures~* Stable health status~* Access to consistent and reliable means of telephone contact~* Able to understand and comply with planned study procedures~* Agree to stay in contact with site, and no plans to move from study area for study duration~Exclusion Criteria:~* Allergic to eggs, other vaccine components, or squalene-based adjuvants~* Women with positive pregnancy test within 24 hours of vaccination, or are breastfeeding~* Females of childbearing potential who refuse acceptable birth control, if sexually active, have not used birth control for 2 months prior to study entry~* Have immunosuppression or use anticancer chemotherapy or radiation therapy within preceding 36 months~* Have an active neoplastic disease or history of hematologic malignancy~* Have long term use (≥14 consecutive days) of glucocorticoids (\>20 mg/day) or high-dose inhaled steroids (\>800 mcg/day) within preceding 6 months~* Diagnosis of schizophrenia, bipolar disease, or major psychiatric diagnosis~* Have been hospitalized for psychiatric illness, attempted suicide or deemed danger to self or others within past 10 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk) (Type: EXPERIMENTAL): Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
- 15 mcg H5N1 (monobulk) Plus MF59 (monobulk) (Type: EXPERIMENTAL): Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
- 7.5 mcg H5N1 (monobulk) Plus MF59 (vials) (Type: EXPERIMENTAL): Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
- 15 mcg H5N1 (monobulk) Plus MF59 (vials) (Type: EXPERIMENTAL): Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
- 90 mcg H5N1 (monobulk) without MF59 (Type: EXPERIMENTAL): Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
- 90 mcg H5N1 (vials) without MF59 (Type: EXPERIMENTAL): Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete